Prometheus Therapeutics Inc. — SEC Form D Filing

Prometheus Therapeutics Inc. filed an SEC Form D on April 15, 2026, reporting $2.75M raised in Health Care.

Form D filing details

Filing
SEC Form D
Filing date
April 15, 2026
Amount reported
$2.75M
Round stage
Seed
Industry
Health Care
Website
https://www.prometheustherapeutics.com/

What the company does

Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Prometheus Therapeutics addresses various vascular diseases and neurodegenerative conditions such as Alzheimer's and Parkinson's. They also tackle inflammatory disorders and spinal cord injuries.

Solution

The company utilizes photobiomodulation therapy to stimulate natural regenerative processes in the body, promoting healing through a non-invasive approach.

Why now

There is a growing need for innovative non-invasive treatments for chronic and degenerative diseases, making the timing for such therapies critical.

Verdict

Investors backed Prometheus Therapeutics because they saw potential in a non-invasive treatment method for chronic conditions, betting on the increasing demand for alternatives to traditional invasive solutions. This cleared because the narrative positioned a timely innovation in regenerative medicine, not because the competitive landscape was solidly differentiated. The limited upside comes from potential regulatory hurdles and the risk of limited market adoption if existing therapies maintain their foothold.

Source: SEC EDGAR Form D filing